In early 2022, the Bill and Melinda Gates Foundation (BMGF), in an effort to foster neglected disease drug discovery in countries that are most affected by these diseases, awarded a grant jointly to the University of Ghana in Accra, the…
Lgenia’s Chief Executive Officer and Chief Scientific Officer, Dr. Philip Hipskind, recently multi-authored the paper “The Tuberculosis Drug Accelerator at year 10: what have we learned?” in the journal Nature Medicine. The Tuberculosis Drug Accelerator, an experiment designed to facilitate…
Indianapolis, Indiana; March 2, 2020 – LGENIA, an Indiana-based biotechnology company which has to date focused on its partnership with the TB Drug Accelerator (sponsored by the Bill and Melinda Gates Foundation) announces today that it will collaborate with the…
At the spring 2018 meeting of the Bill and Melinda Gates Foundation’s TB Drug Accelerator, two new institutions were elected as full member collaborators – Harvard University and LGENIA! We now join 20 other member organizations in this important mission,…